Dr. Jennifer Wargo, MD

• General Surgery

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Pennsylvania Perelman School Of Medicine

  Medical School, 1998

• Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial, 2023-03-16

• Multi-modal molecular programs regulate melanoma cell state, 2022-07-09

• Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer, 2021-08-19

• B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density, 2019-02-26

• Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon, 2020-01-21

• An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition, 2017-06-05

• Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response, 2021-12-23

• Gut microbes' impact on oncogenic drivers: location matters, 2020-09-17

• Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma, 2014-12-08

• Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma, 2017-04-28

• A pre-existing rare PIK3CAE545Ksubpopulation confers clinical resistance to MEK plus CDK4/6 inhibition inNRASmelanoma and is dependent on S6K1 signaling, 2018-03-01

• Future perspectives in melanoma research Meeting report from the "Melanoma Bridge”. Napoli, December 1st-4th 2015, 2016-11-15

• Hallmarks of response, resistance, and toxicity to immune checkpoint blockade, 2021-10-07

• The immune-microenvironment confers resistance to MAP kinase pathway inhibitors through macrophage-derived TNFa, 2014-08-01

• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021-02-18

• Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade, 2017-08-10

• The State of Melanoma: Challenges and Opportunities, 2016-04-17

• Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment, 2022-11-16

• Neoadjuvant Therapy for Melanoma - New and Evolving Concepts, 2022-04-25

• The gut microbiome modulates response to cancer immunotherapy, 2020-03-06

• Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy, 2015-06-03

• Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma, 2020-04-15

• Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1, 2021-06-29

• Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy, 2019-05-29

• Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype, 2020-09-11

• PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hicells and anti-PD-1 resistance, 2019-07-29

• Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, 2018-09-24

• Effective innate and adaptive anti-melanoma immunity through localized TLR-7/8 activation, 2014-09-24

• Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy, 2017-01-28

• The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View, 2020-02-07

• Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy, 2016-03-14

• Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis, 2018-11-12

• Future perspectives in melanoma research "Melanoma Bridge”, Napoli, November 30th-3rd December 2016, 2017-11-16

• Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure, 2017-06-12

• Bacteroides ovatusalleviates dysbiotic microbiota-induced intestinal graft-versus-host disease, 2023-01-31

• Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results, 2023-03-30

• Defining T cell states associated with response to checkpoint immunotherapy in melanoma, 2018-11-01

• A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh/AXLlowmelanoma, 2018-10-19

• Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment, 2023-01-27

• Interaction of molecular alterations with immune response in melanoma, 2017-06-01

• The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy, 2018-04-09

• Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma, 2023-03-09

• Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma, 2023-07-15

• Glioma and the gut-brain axis: opportunities and future perspectives, 2022-04-14

• Mucus-degrading Bacteroides link carbapenems to aggravated graft-versushost disease, 2022-09-29

• Tumor MHC Class I Expression Associates with Intralesional Interleukin-2 Response in Melanoma, 2022-03-01

• Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis, 2015-11-10

• MITF Modulates Therapeutic Resistance through EGFR Signaling, 2015-03-19

• Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab, 2020-01-03

• Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer, 2021-10-01

• Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases, 2019-02-20

• B cells and tertiary lymphoid structures promote immunotherapy response, 2020-01-15

• Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma, 2020-02-12

• The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma, 2022-11-02

• Considerations for designing preclinical studies in cancer immune nanomedicine, 2020-12-21

• Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine, 2017-09-15

• Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation, 2015-05-28

• Identification of bacteria-derived HLA-bound peptides in melanoma, 2021-03-17

• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance, 2017-03-01

• Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy, 2018-05-04

• Monitoring immune responses in the tumor microenvironment, 2016-05-27

• Comprehensive T cell repertoire characterization of non-small cell lung cancer, 2020-01-30

• Neoadjuvant relatlimab and nivolumab in resectable melanoma, 2022-10-26

• Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients, 2018-02-12

• Microbiome influencers of checkpoint blockade-associated toxicity, 2023-01-09

• Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes, 2021-10-22

• Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade, 2016-06-14

• RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma, 2014-10-16

• The microbiome and human cancer, 2021-03-26

• The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, 2018-02-12

• Gene targeting meets cell-based therapy: raising the tail, or merely a whimper?, 2016-11-11

• Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma, 2016-05-10

• The human tumor microbiome is composed of tumor type-specific intracellular bacteria, 2020-05-29

• Obesity is associated with altered tumor metabolism in metastatic melanoma, 2023-01-04

• Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set, 2016-10-25

• Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma, 2017-04-07

• Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer, 2019-05-01

• Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, 2021-06-29

• PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation, 2014-03-31

• Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy, 2022-06-15

• Primary, Adaptive and Acquired Resistance to Cancer Immunotherapy, 2017-02-09

• Immunotherapy resistance: the answers lie ahead - not in front - of us, 2017-02-21

• Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma, 2018-09-12

• Loss of PTEN promotes resistance to T cell-mediated immunotherapy, 2015-12-08

• Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment, 2021-10-07

• Gut microbiome modulation via fecal microbiota transplant to augment immunotherapy in patients with melanoma or other cancers, 2020-06-24

• A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma, 2017-11-14

• Loss of IFN-?pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy, 2016-09-22